These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 3466340

  • 1. [Effectiveness and toxicity of high-dosage Ara-C. Clinical observations in 10 cases and review of the literature].
    Morant R, Hofmann V, Honegger HP, Gmür J, Fehr J, Sauter C.
    Schweiz Med Wochenschr; 1986 Oct 11; 116(41):1415-9. PubMed ID: 3466340
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.
    Brito-Babapulle F, Catovsky D, Slocombe G, Newland AC, Marcus RE, Goldman JM, Galton DA.
    Cancer Treat Rep; 1987 Feb 11; 71(2):161-3. PubMed ID: 3467843
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Results of therapy with high-dose cytosine arabinoside].
    Pralle H, Breithaupt H.
    Onkologie; 1985 Feb 11; 8(1):48, 50-2. PubMed ID: 3885122
    [Abstract] [Full Text] [Related]

  • 8. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
    Yoshida M, Owada N, Sasaki R, Sakamoto S, Miura Y.
    Gan To Kagaku Ryoho; 1986 Jan 11; 13(1):143-6. PubMed ID: 3455805
    [Abstract] [Full Text] [Related]

  • 9. [Cytosine-arabinoside in high doses in refractory acute granulocytic leukemia. Apropos of 17 cases].
    Jouet JP, Simon M, Fenaux P, Pollet JP, Bauters F.
    Nouv Rev Fr Hematol (1978); 1985 Jan 11; 27(3):169-73. PubMed ID: 3862072
    [Abstract] [Full Text] [Related]

  • 10. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN, Fernández-Jurado A, Martino ML, Diéguez JC, Moreno MV, Quesada JA, Polo B, Cañavate M, Amian A, Prados D.
    Sangre (Barc); 1998 Feb 11; 43(1):35-9. PubMed ID: 9580427
    [Abstract] [Full Text] [Related]

  • 11. Low-dose cytosine arabinoside (LD-Ara C) treatment in dysmyelopoietic syndromes (DMPS) and acute myelogenous leukemia (AML).
    Jehn U, Göldel N, Vehling-Kaiser U.
    Anticancer Res; 1987 Feb 11; 7(3 Pt B):505-8. PubMed ID: 3477124
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [High-dose cytarabine treatment: a promising therapy modality in acute resistant myeloid leukemias in recurrence].
    Meusers P, Heidemann H, Lunscken C, Uppenkamp M, Zou P, Brittinger G.
    Onkologie; 1985 Feb 11; 8(1):16, 18-9. PubMed ID: 3885115
    [Abstract] [Full Text] [Related]

  • 15. High dose ARA-C as induction therapy of acute myeloid leukaemia.
    Minigo H, Nemet D, Planinc-Peraica A, Bogdanic V, Labar B, Jaksic B, Hauptmann E.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990 Feb 11; 117(1):135-40. PubMed ID: 1695167
    [Abstract] [Full Text] [Related]

  • 16. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.
    Leuk Res; 2008 Dec 11; 32(12):1830-6. PubMed ID: 18571721
    [Abstract] [Full Text] [Related]

  • 17. Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside--the Taiwan experience.
    Chen YC, Lin SF, Yao M, Chen TY, Tsao CJ, Chen TP.
    Semin Hematol; 1996 Oct 11; 33(4 Suppl 3):30-4. PubMed ID: 8916314
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.